European Journal of Clinical Microbiology & Infectious Diseases

(The H4-Index of European Journal of Clinical Microbiology & Infectious Diseases is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-10-01 to 2023-10-01.)
Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards647
Classification of COVID-19 patients from chest CT images using multi-objective differential evolution–based convolutional neural networks395
COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection349
The epidemiology and clinical information about COVID-19346
The genetic sequence, origin, and diagnosis of SARS-CoV-2272
Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome159
Influenza and antiviral resistance: an overview157
The effects of inulin on gut microbial composition: a systematic review of evidence from human studies95
Transmission of SARS-CoV-2: an update of current literature90
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening88
Leptospirosis: a neglected tropical zoonotic infection of public health importance—an updated review87
Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: a narrative review84
Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship83
Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile73
Application of metagenomic next-generation sequencing for bronchoalveolar lavage diagnostics in critically ill patients69
Vertical transmission of SARS-CoV-2 infection and preterm birth68
Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak63
Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review61
Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in France56
Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV54
The Allplex 2019-nCoV (Seegene) assay: which performances are for SARS-CoV-2 infection diagnosis?52
Virulence of Helicobacter pylori outer membrane proteins: an updated review48
Virulence factors and clonal diversity of Staphylococcus aureus in colonization and wound infection with emphasis on diabetic foot infection48
Diagnostic and medical needs for therapeutic drug monitoring of antibiotics46
Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study44
Mechanism of Candida pathogenesis: revisiting the vital drivers44
Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting42
Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-241
Clinical patterns of somatic symptoms in patients suffering from post-acute long COVID: a systematic review40
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa39
Effectiveness of favipiravir in COVID-19: a live systematic review37
Impact of rapid multiplex PCR on management of antibiotic therapy in COVID-19-positive patients hospitalized in intensive care unit37
Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae37
Clinical performance of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals with COVID-1936
Evaluation of three commercial assays for SARS-CoV-2 molecular detection in upper respiratory tract samples36
Combined throat/nasal swab sampling for SARS-CoV-2 is equivalent to nasopharyngeal sampling36